Want to see SG:8YY full AI Analyst Report?
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$60.67M
Enterprise ValueS$74.41
Total Cash (Recent Filing)S$494.00K
Total Debt (Recent Filing)S$378.00K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA near-200% revenue rebound to ~5.3m in 2025 signals improved commercialization and market traction for the company’s diagnostic offerings. Sustained top-line growth can support scale economies, higher recurring consumable sales, and provides a basis for future margin improvement if operating leverage is realized.
Consumable-driven Business ModelA product mix focused on test kits, consumables and supporting instruments creates a recurring revenue profile as tests are repeatable per patient. This durable model can produce predictable per-test revenue and high lifetime customer value once distribution and clinical adoption scale, supporting long-term cash flow stability.
Exposure To Diagnostic TailwindsOperating in blood-based clinical diagnostics ties the business to structural healthcare trends like aging populations, increased screening and chronic disease monitoring. These long-term secular drivers expand addressable markets and can sustain product demand over multiple years if the company secures clinical adoption and reimbursement pathways.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flows mean the business does not yet self-fund operations or growth. Continued cash burn forces reliance on external financing, which can dilute shareholders or be constrained in downturns, and limits ability to invest organically in commercialization, R&D, or manufacturing capacity.
Thin Equity, Meaningful DebtDebt materially exceeds the equity cushion, and a history of negative equity indicates balance-sheet fragility. Limited capital resilience reduces financial flexibility to weather operational shocks, raises refinancing risk, and can increase borrowing costs, constraining strategic options like scaling sales or funding regulatory work.
Chronic Unprofitability And Margin UncertaintyRepeated operating and net losses show the company has not yet achieved profitable unit economics or consistent margins. Without demonstrated operating leverage, sustained profitability is uncertain; ongoing losses risk repeated capital raises and impede the transition to self-sustaining free cash flow over the medium term.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$60.67M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Nov 04, 2026 which is in 78 days.
How were Biolidics Ltd.’s earnings last quarter?
Biolidics Ltd. released its earnings results on Aug 12, 2026. The company reported S$0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Biolidics Ltd. reported an EPS of S$0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a Singapore-based medical technology firm, specializes in precision medicine, focusing on developing diagnostic solutions. Operating across Japan, Hong Kong, Thailand, Malaysia, and the United States, its business is structured into Cancer, Infectious Diseases, and Laboratory Services segments. The company's key innovations include the ClearCell FX1 System, an automated device that, using Streck Cell-free DNA BCT and EDTA tubes, isolates intact and viable circulating tumor cells (CTCs) from small blood samples. It also provides the CTChip FR1 biochip for separating CTCs from leukocytes, alongside offering general laboratory services. Established in 2009, the company was formerly known as Biolidics Limited, adopting its current name in June 2025.
Technical Analysis
Cordlife Group
―
ISEC Healthcare Ltd
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Singapore Institute of Advanced Medicine Holdings Ltd.
―